

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 3, 2025

CD69

RRID:AB_2738441

Type: Antibody

Proper Citation

(BD Biosciences Cat# 563834, RRID:AB_2738441)

Antibody Information

URL: http://antibodyregistry.org/AB_2738441

Proper Citation: (BD Biosciences Cat# 563834, RRID:AB_2738441)

Target Antigen: CD69

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD69

Description: This monoclonal targets CD69

Target Organism: baboon, cynomolgus, rhesus, human

Clone ID: FN50 (also known as FN 50)

Antibody ID: AB_2738441

Vendor: BD Biosciences

Catalog Number: 563834

Record Creation Time: 20231110T033526+0000

Record Last Update: 20240725T051403+0000

Ratings and Alerts

No rating or validation information has been found for CD69.

No alerts have been found for CD69.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Galsky MD, et al. (2024) Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. *Cell reports. Medicine*, 5(2), 101393.

Stavarakaki E, et al. (2024) An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma. *Cell reports methods*, 4(3), 100716.

Krämer B, et al. (2023) Single-cell RNA sequencing identifies a population of human liver-type ILC1s. *Cell reports*, 42(1), 111937.

Jayaraman S, et al. (2023) Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses. *Cell reports methods*, 3(10), 100600.

Cheng J, et al. (2022) IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells. *iScience*, 25(1), 103588.

Choi J, et al. (2021) Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. *Cell reports methods*, 1(5), 100084.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. *Cell reports. Medicine*, 1(8), 100141.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.